Pharma major, AstraZeneca, is investing $300-mn in a new facility in Rockville, Maryland (USA) to launch its cell therapy platforms in the US for critical cancer trials and future commercial supply.
The facility will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas, the company informed.
The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics, AbelZeta, Cellectis, and the acquisition of Neogene Therapeutics.
The Rockville facility is located less than five miles away from one of the company’s five global R&D centres and sits within the booming life sciences corridor in Maryland. With close proximity to several universities, the life sciences ecosystem provides an attractive environment for recruiting new and experienced talent, the company said.
The Rockville facility will join AstraZeneca’s global manufacturing and supply network of nearly 30 manufacturing and supply sites in 16 countries, which are either currently operational or under development. In the US, AstraZeneca’s manufacturing sites focus on the production of small molecules and biologics.
Ms. Pam Cheng, Executive Vice President of Global Operations & IT and Chief Sustainability Officer, AstraZeneca, said, “This new $300-mn investment will accelerate our ambition to make next-generation cell therapy a reality, ensuring that we are ready to scale and meet the demands of patients.”
AstraZeneca is building a cell therapy portfolio that aims to empower and equip the immune system’s T-cells to more effectively fight cancer. The company’s research teams are exploring new ways to target and arm CAR-Ts to increase their effectiveness in solid tumours by overcoming the immune-suppressive tumour microenvironment. Looking to the future, AstraZeneca is working to engineer next-generation cell therapies, where physicians could potentially select from a library of off-the-shelf patient-ready therapies already developed from the cells of healthy donors.


9 February, 2024 13:51:09 IST 
















